pimagedine has been researched along with Complications of Diabetes Mellitus in 22 studies
pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure
aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pyridoxamine is a post-Amadori AGE inhibitor-that is, an "Amadorin"-whereas aminoguanidine primarily scavenges reactive dicarbonyl precursors to AGEs." | 2.43 | Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. ( Chen, Y; Khalifah, RG; Wassenberg, JJ, 2005) |
| "AGEs accumulate in renal failure as a result of decreased excretion and increased generation resulting from oxidative and carbonyl stress of uremia." | 2.41 | Advanced glycation end products: a Nephrologist's perspective. ( Choudhury, D; Levi, M; Raj, DS; Welbourne, TC, 2000) |
| "Hyperglycemia is considered a key causal factor in the development of diabetic vascular complications and can mediate its adverse effects through multiple pathways." | 2.41 | Glycation as the glucose link to diabetic complications. ( Gugliucci, A, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 9 (40.91) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, S | 1 |
| Khan, MS | 1 |
| Alouffi, S | 1 |
| Khan, S | 1 |
| Khan, M | 1 |
| Akashah, R | 1 |
| Faisal, M | 1 |
| Shahab, U | 1 |
| Spasov, AA | 1 |
| Babkov, DA | 1 |
| Sysoeva, VA | 1 |
| Litvinov, RA | 1 |
| Shamshina, DD | 1 |
| Ulomsky, EN | 1 |
| Savateev, KV | 1 |
| Fedotov, VV | 1 |
| Slepukhin, PA | 1 |
| Chupakhin, ON | 1 |
| Charushin, VN | 1 |
| Rusinov, VL | 1 |
| Bavkar, LN | 1 |
| Patil, RS | 1 |
| Rooge, SB | 1 |
| Nalawade, ML | 1 |
| Arvindekar, AU | 1 |
| Jung, E | 1 |
| Kim, J | 1 |
| Kim, SH | 1 |
| Kim, S | 1 |
| Cho, MH | 1 |
| Zhou, XY | 1 |
| Zhang, F | 1 |
| Ying, CJ | 1 |
| Chen, J | 1 |
| Chen, L | 1 |
| Dong, J | 1 |
| Shi, Y | 1 |
| Tang, M | 1 |
| Hu, XT | 1 |
| Pan, ZH | 1 |
| Xu, NN | 1 |
| Zheng, KY | 1 |
| Tang, RX | 1 |
| Song, YJ | 1 |
| Muthenna, P | 1 |
| Akileshwari, C | 1 |
| Saraswat, M | 1 |
| Bhanuprakash Reddy, G | 1 |
| Nordquist, L | 1 |
| Liss, P | 1 |
| Fasching, A | 1 |
| Hansell, P | 1 |
| Palm, F | 1 |
| Ozturk, A | 1 |
| Fırat, C | 1 |
| Parlakpınar, H | 1 |
| Bay-Karabulut, A | 1 |
| Kirimlioglu, H | 1 |
| Gurlek, A | 1 |
| Jakus, V | 1 |
| Rietbrock, N | 1 |
| Khalifah, RG | 2 |
| Chen, Y | 1 |
| Wassenberg, JJ | 1 |
| Cantero, AV | 1 |
| Portero-Otín, M | 1 |
| Ayala, V | 1 |
| Auge, N | 1 |
| Sanson, M | 1 |
| Elbaz, M | 1 |
| Thiers, JC | 1 |
| Pamplona, R | 1 |
| Salvayre, R | 1 |
| Nègre-Salvayre, A | 1 |
| Montagnani, M | 1 |
| Wolffenbuttel, BH | 1 |
| Huijberts, MS | 1 |
| Booth, AA | 1 |
| Hudson, BG | 1 |
| Friedman, EA | 1 |
| Raj, DS | 1 |
| Choudhury, D | 1 |
| Welbourne, TC | 1 |
| Levi, M | 1 |
| Zhang, J | 1 |
| Ren, S | 1 |
| Shen, GX | 1 |
| Gugliucci, A | 1 |
| Price, DL | 1 |
| Rhett, PM | 1 |
| Thorpe, SR | 1 |
| Baynes, JW | 1 |
| Du, Y | 1 |
| Smith, MA | 1 |
| Miller, CM | 1 |
| Kern, TS | 1 |
| Brownlee, M | 2 |
7 reviews available for pimagedine and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Advanced glycation end-products and the progress of diabetic vascular complications.
Topics: Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Glycation End Products, Advanced; Glyco | 2004 |
Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Drug Design; Glycation End Product | 2005 |
Will pimagidine improve survival of diabetics on dialysis?
Topics: Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Glycation End Products, Advanced; Guani | 1996 |
Advanced glycation end products: a Nephrologist's perspective.
Topics: Aging; Arteriosclerosis; Cross-Linking Reagents; Diabetes Complications; Glycation End Products, Adv | 2000 |
Glycation as the glucose link to diabetic complications.
Topics: Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Glycated Hemoglo | 2000 |
Glycation products and the pathogenesis of diabetic complications.
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Retino | 1992 |
Pharmacological modulation of the advanced glycosylation reaction.
Topics: Animals; Blood Proteins; Chemical Phenomena; Chemistry; Diabetes Complications; Diabetes Mellitus; G | 1989 |
15 other studies available for pimagedine and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Gold Nanoparticle-Bioconjugated Aminoguanidine Inhibits Glycation Reaction: An
Topics: Animals; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Experimental; Disease Models, Ani | 2021 |
6-Nitroazolo[1,5-a]pyrimidin-7(4H)-ones as Antidiabetic Agents.
Topics: alpha-Glucosidases; Diabetes Complications; Dipeptidyl Peptidase 4; Drug Design; Glycation End Produ | 2017 |
Acceleration of protein glycation by oxidative stress and comparative role of antioxidant and protein glycation inhibitor.
Topics: Animals; Antioxidants; Diabetes Complications; Glycation End Products, Advanced; Guanidines; Male; O | 2019 |
Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo.
Topics: Animals; Collagen; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipept | 2014 |
Inhibition of iNOS alleviates cognitive deficits and depression in diabetic mice through downregulating the NO/sGC/cGMP/PKG signal pathway.
Topics: Animals; Brain; Cognition Disorders; Depressive Disorder; Diabetes Complications; Diabetes Mellitus, | 2017 |
Inhibition of advanced glycation end-product formation on eye lens protein by rutin.
Topics: Animals; Chelating Agents; Crystallins; Diabetes Complications; Free Radical Scavengers; Glycation E | 2012 |
Hypoxia in the diabetic kidney is independent of advanced glycation end-products.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Inh | 2013 |
Beneficial effects of aminoguanidine on skin flap survival in diabetic rats.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Experimental; Femal | 2012 |
Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis.
Topics: Animals; Aorta; Apolipoproteins E; Arginine; Atherosclerosis; Becaplermin; Cell Movement; Cell Proli | 2007 |
Diabetic cardiomyopathy: how much does it depend on AGE?
Topics: Animals; Cardiomyopathies; Diabetes Complications; Disease Models, Animal; Drug Delivery Systems; En | 2008 |
Aminoguanidine, a potential drug for the treatment of diabetic complications.
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Guanidines; Hum | 1993 |
Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine.
Topics: Animals; Antigens; Cattle; Diabetes Complications; Diabetes Mellitus; Enzyme Inhibitors; Glycation E | 1996 |
Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells.
Topics: Biomarkers; Blotting, Northern; Cardiovascular Diseases; Cells, Cultured; Diabetes Complications; Di | 2000 |
Chelating activity of advanced glycation end-product inhibitors.
Topics: Amines; Antioxidants; Ascorbic Acid; Bromides; Chelating Agents; Copper; Diabetes Complications; Dia | 2001 |
Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine.
Topics: Animals; Cattle; Cells, Cultured; Cyclic GMP; Diabetes Complications; Diabetes Mellitus; Diabetic Re | 2002 |